Point prevalence captures migraine at a particular time, whereas period prevalence covers a defined interval and lifetime prevalence records whether a person has ever experienced it. Choosing among these measures changes the population-level picture researchers obtain, so the selected timeframe must match the epidemiological question being investigated.
Structured surveys, clinical interviews, and medical records provide different routes for identifying possible migraine cases. Applying standardized diagnostic criteria to those sources gives researchers a defined basis for deciding which reports or records count in an estimate. The chosen source and criteria therefore shape how consistently cases are recognized across epidemiological studies.
Comparing estimates across age, sex, and geography shows whether migraine burden is distributed evenly or concentrated in particular groups or locations. These patterns do not by themselves establish a biological cause, but they help neuroscientists formulate questions about migraine biology and risk factors and identify populations that warrant closer study.
An estimate is meaningful only in relation to the population and period from which it was derived. Reporting those boundaries lets readers interpret whether the result reflects a moment, an interval, or lifetime experience and compare patterns across demographic groups without treating unlike measurements as equivalent.
Researchers first define the population and the time frame, then collect information through a structured survey, clinical interview, or medical-record review. Standardized diagnostic criteria are used to identify migraine cases, after which the number of identified cases is related to the population studied. This workflow produces the selected prevalence measure for analysis.
Migraine prevalence data support decisions beyond case counting. Health planners can use them to characterize population-level burden and recognize groups with unmet treatment needs. Investigators can also use the estimates to support migraine biology and risk-factor research, while public health teams can establish a baseline for evaluating prevention strategies and other interventions.